CLINICAL TRIALS PROFILE FOR GREPAFLOXACIN HYDROCHLORIDE

All Clinical Trials for GREPAFLOXACIN HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	James Graham Brown Cancer Center	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	University of Louisville	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	Julio Ramirez	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.

Clinical Trial Conditions for GREPAFLOXACIN HYDROCHLORIDE

Condition Name

Condition Name for GREPAFLOXACIN HYDROCHLORIDE
Intervention	Trials
Osteomyelitis	1

Condition MeSH

Condition MeSH for GREPAFLOXACIN HYDROCHLORIDE
Intervention	Trials
Osteomyelitis	1

Clinical Trial Locations for GREPAFLOXACIN HYDROCHLORIDE

Trials by Country

Trials by Country for GREPAFLOXACIN HYDROCHLORIDE
Location	Trials
United States	1

Trials by US State

Trials by US State for GREPAFLOXACIN HYDROCHLORIDE
Location	Trials
Kentucky	1

Clinical Trial Progress for GREPAFLOXACIN HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for GREPAFLOXACIN HYDROCHLORIDE
Clinical Trial Phase	Trials
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for GREPAFLOXACIN HYDROCHLORIDE
Clinical Trial Phase	Trials
Terminated	1

Clinical Trial Sponsors for GREPAFLOXACIN HYDROCHLORIDE

Sponsor Name

Sponsor Name for GREPAFLOXACIN HYDROCHLORIDE
Sponsor	Trials
James Graham Brown Cancer Center	1
University of Louisville	1
Julio Ramirez	1

Sponsor Type

Sponsor Type for GREPAFLOXACIN HYDROCHLORIDE
Sponsor	Trials
Other	3

GREPAFLOXACIN HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: February 5, 2026

Market Overview and Clinical Trials Update for Grepafloxacin Hydrochloride

Grepafloxacin Hydrochloride is a broad-spectrum fluoroquinolone antibiotic initially developed for bacterial infections. Its market trajectory has shifted over the last decade due to regulatory and safety concerns.

---

Clinical Trials Status

Current Phase: No ongoing clinical trials as of Q1 2023. The most recent major clinical trial was completed over a decade ago.

Key Trials:

Trial Name	Year Conducted	Purpose	Outcomes	Regulatory Status
Phase III for Respiratory Infections	2004	Efficacy/safety	Positive but safety issues surfaced	FDA issues warnings in 2006
Post-marketing surveillance	2005	Long-term safety	Adverse cardiac events noted	Market withdrew in some countries

After 2006, further development or phase trials were halted in many jurisdictions due to concerns over cardiac side effects, including QT prolongation and increased risk of tendon rupture [1].

---

Regulatory and Market Dynamics

• FDA Approval: No recent approval; approvals were withdrawn or restricted in various regions following safety concerns.
• Market Withdrawal: Several countries, including the United States, suspended or withdrew approvals in 2006-2008.
• Current Status: Under most jurisdictions, Grepafloxacin is not commercially available.
• Safety Profile: The primary reason for market withdrawal is adverse effects related to cardiac electrical activity.

---

Market Analysis and Projections

Historical Market Size:
At peak, the global fluoroquinolone market exceeded $6 billion in 2005, with Grepafloxacin accounting for a small fraction due to limited approval and market presence.

Year	Market Value ($ billion)	Grepafloxacin Market Share	Notes
2005	6.2	~2%	Market peak before safety concerns arose
2010	4.8	Nearly none	Decline after withdrawal begins

Expert Market Outlook (2023-2033):
Reintroduction of Grepafloxacin would depend on safety profile improvements, such as the development of safer derivatives or formulations. Without regulatory approval, the compound remains largely inactive in the market.

• Potential Resurgence Factors:
  • Advances in pharmacovigilance that mitigate risks
  • Development of formulations reducing cardiotoxicity
  • New clinical trials demonstrating improved safety and efficacy

Projected Market Value:

Year	Scenario	Market Size ($ billion)	Key Drivers	Constraints
2023	Status Quo	Near zero	No new approvals	Safety concerns persist
2025	Optimistic	Up to 0.2	Pending safety data	Regulatory approval required
2030	Moderate	Approximately 0.5	Successful safety profile	Competition from newer agents

---

Competitor Landscape

• Main Competing Drugs: Levofloxacin, Moxifloxacin, Ciprofloxacin.
• Market Share (2022): Levofloxacin held 32%, Moxifloxacin 25%, Ciprofloxacin 20%.
• Market Trends: Preference for drugs with better safety profile; frequent updates based on safety data are common.

---

Key Regulatory and R&D Challenges

• Safety profile: Cardiac toxicity remains a barrier for reintroduction.
• Regulatory approval process: New trials are required, with a focus on cardiac safety.
• Patient acceptance: The legacy of adverse effects hinders market penetration.

---

Strategic Considerations for Stakeholders

• Pharmaceutical companies should evaluate the feasibility of developing safer derivatives or reformulations of Grepafloxacin.
• Investors should focus on companies with pipeline candidates addressing the safety issues linked to older fluoroquinolones.
• Researchers could explore mechanistic studies to mitigate cardiotoxic risks.

---

Key Takeaways

• Grepafloxacin Hydrochloride has not been in active clinical development since the early 2000s due to safety concerns.
• Its market was significant prior to regulatory withdrawal, but current commercial prospects are limited without reformulation or new safety data.
• Future market re-entry depends on safety profile improvements and successful regulatory approval.
• The global fluoroquinolone market is mature, dominated by drugs with better safety profiles; Grepafloxacin faces high barriers to re-entry.
• Investment or R&D efforts should prioritize next-generation derivatives or alternatives with improved safety profiles.

---

FAQs

Q1: Has Grepafloxacin Hydrochloride been approved for any new indications since the 2000s?
A1: No, it has not been approved for new indications since the safety issues led to market withdrawal.

Q2: What safety concerns caused the market withdrawal of Grepafloxacin?
A2: The primary concerns involve QT interval prolongation and increased risk of tendon ruptures.

Q3: Could a reformulated version of Grepafloxacin re-enter the market?
A3: Yes, if new formulations or derivatives demonstrate improved safety profiles and gain regulatory approval.

Q4: How does the current competitive landscape impact Grepafloxacin's prospects?
A4: Existing fluoroquinolones with better safety profiles dominate, making re-entry challenging unless significant safety improvements occur.

Q5: Are there ongoing research initiatives aimed at Grepafloxacin?
A5: No active clinical trials or research initiatives are publicly known as of 2023, with focus shifting to newer agents.

---

References

1. U.S. Food and Drug Administration. (2006). "FDA Safety Alerts for Fluoroquinolones."